Summary of treatment for (A) ER- and PgR-positive tumors, (B) luminal A, luminal B, HER2-positive, triple-negative breast cancers, and (C) HER2-positive and HER2-negative tumors. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.